• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷霉素对产 ESBL 和/或碳青霉烯酶肠杆菌科的药效学研究。

Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.

机构信息

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.

出版信息

J Antimicrob Chemother. 2017 Dec 1;72(12):3374-3381. doi: 10.1093/jac/dkx328.

DOI:10.1093/jac/dkx328
PMID:29029067
Abstract

BACKGROUND

The increase in antibiotic resistance in Gram-negative bacteria and the limited therapeutic options due to the shortage of new antibiotics have increased the interest of the 'old' antibiotic fosfomycin in the treatment of infections. However, there are contradictory reports on the pharmacodynamics of and emergence of resistance to fosfomycin.

METHODS

Time-kill assays were performed with 11 ESBL-positive and 3 ESBL-negative strains, exposing the bacteria to 2-fold static concentrations from 0.125× to 32× MIC. The sigmoid maximum effect (Emax) model was fitted to the time-kill curve data. Amplification of resistance over time was evaluated under various conditions of selective pressure by plating on 16× MIC plates.

RESULTS

Fosfomycin was bactericidal for all strains within 8 h. Using the Emax model, no significant differences between strains were observed for the pharmacodynamic parameters. However, the large variation in Hill slope factors for Escherichia coli of 0.87 up to 4.02 indicates that the killing behaviour appears to be more time dependent for some strains but concentration dependent for others. In the fosfomycin-exposed cultures under low and high selective pressure (≥2× MIC) the median resistance proportions between the resistant and total population increased from ≤2 × 10-6 (T = 0 h) to 0.652-0.899 (T = 24 h). Resistance appeared stable after repeated subculturing.

CONCLUSIONS

Killing behaviour of fosfomycin does not only differ between species but also within species and may have an impact on the design of optimal dosing regimens. Although fosfomycin was bactericidal against all strains (re)growth of resistant subpopulations occurred relatively fast. This may limit the use of fosfomycin as a single drug therapy.

摘要

背景

革兰氏阴性菌的抗生素耐药性增加,以及由于新抗生素短缺而导致治疗选择有限,这增加了人们对旧抗生素磷霉素治疗感染的兴趣。然而,关于磷霉素的药效学和耐药性的出现存在相互矛盾的报道。

方法

使用 11 株 ESBL 阳性和 3 株 ESBL 阴性菌株进行时间杀伤试验,将细菌暴露于 2 倍静态浓度,从 0.125×至 32×MIC。将最大效应(Emax)模型拟合到时间杀伤曲线数据中。在不同的选择压力条件下通过在 16×MIC 平板上进行平板接种来评估随时间的耐药性扩增。

结果

磷霉素在 8 小时内对所有菌株均具有杀菌作用。使用 Emax 模型,在药效学参数方面,菌株之间没有观察到显著差异。然而,大肠杆菌的希尔斜率因子的变化范围从 0.87 到 4.02 很大,这表明某些菌株的杀菌行为似乎更依赖于时间,而另一些菌株则依赖于浓度。在低和高选择压力(≥2×MIC)下,暴露于磷霉素的培养物中,耐药和总群体之间的中位耐药比例从≤2 × 10-6(T=0 小时)增加到 0.652-0.899(T=24 小时)。经过反复传代后,耐药性似乎稳定。

结论

磷霉素的杀菌行为不仅在不同物种之间有所不同,而且在同一物种内也有所不同,这可能会影响最佳给药方案的设计。尽管所有菌株(再)生长的耐药亚群都相对较快地出现,磷霉素对所有菌株均具有杀菌作用。这可能限制了磷霉素作为单一药物治疗的使用。

相似文献

1
Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.磷霉素对产 ESBL 和/或碳青霉烯酶肠杆菌科的药效学研究。
J Antimicrob Chemother. 2017 Dec 1;72(12):3374-3381. doi: 10.1093/jac/dkx328.
2
The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.在体外药代动力学/药效学模型实验中,多黏菌素与磷霉素联合使用对产 NDM-1 的肠杆菌科具有协同作用。
Int J Antimicrob Agents. 2015 Nov;46(5):560-7. doi: 10.1016/j.ijantimicag.2015.07.019. Epub 2015 Sep 5.
3
Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.呋喃妥因对参与尿路感染的超广谱β-内酰胺酶(ESBL)阳性病原体的药效学及差异活性
J Antimicrob Chemother. 2016 Oct;71(10):2883-9. doi: 10.1093/jac/dkw212. Epub 2016 Jun 7.
4
Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.超广谱β-内酰胺酶时代其他值得关注的抗菌药物:磷霉素、呋喃妥因和替加环素。
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202. doi: 10.1111/j.1469-0691.2007.01852.x.
5
Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.产超广谱β内酰胺酶(ESBL)肠杆菌科导致的尿路感染患者的口服治疗选择。
J Infect Public Health. 2019 Nov-Dec;12(6):843-846. doi: 10.1016/j.jiph.2019.05.012. Epub 2019 Jun 6.
6
Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model.采用体外模型,比较单次口服3克磷霉素后模拟尿液浓度时对大肠杆菌的药效学活性。
Diagn Microbiol Infect Dis. 2017 Jul;88(3):271-275. doi: 10.1016/j.diagmicrobio.2017.04.007. Epub 2017 Apr 23.
7
[Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].[根据美国临床和实验室标准协会(CLSI)及欧洲抗菌药物敏感性试验委员会(EUCAST)建议,产超广谱β-内酰胺酶的尿源大肠埃希菌分离株对磷霉素的敏感性]
Mikrobiyol Bul. 2014 Oct;48(4):545-55.
8
Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.多黏菌素 B 和磷霉素可阻止产 KPC 肺炎克雷伯菌在中空纤维感染模型中定植。
Int J Antimicrob Agents. 2018 Jul;52(1):114-118. doi: 10.1016/j.ijantimicag.2018.02.010. Epub 2018 Feb 24.
9
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.体外研究新型氨基糖苷类药物普拉佐米星单独及与黏菌素、美罗培南、磷霉素或替加环素联合对产碳青霉烯酶肠杆菌科菌株的活性。
Int J Antimicrob Agents. 2015 Dec;46(6):616-21. doi: 10.1016/j.ijantimicag.2015.07.021. Epub 2015 Sep 9.
10
The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.磷霉素对从尿路感染中分离出的产超广谱β-内酰胺酶肠杆菌科细菌的活性:一项为期12年的单中心研究
Microb Drug Resist. 2018 Jun;24(5):607-612. doi: 10.1089/mdr.2017.0097. Epub 2017 Oct 24.

引用本文的文献

1
Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.静脉注射磷霉素治疗生物膜相关骨与关节感染的新观念:文献综述
Microorganisms. 2025 Apr 23;13(5):963. doi: 10.3390/microorganisms13050963.
2
The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy.静脉注射磷霉素在临床实践中的应用:意大利一家三级医院的5年回顾性研究
Antibiotics (Basel). 2023 May 27;12(6):971. doi: 10.3390/antibiotics12060971.
3
Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study.
脑室炎患者中磷霉素的脑脊液穿透性:一项观察性研究。
Ann Clin Microbiol Antimicrob. 2023 Apr 24;22(1):29. doi: 10.1186/s12941-023-00572-4.
4
Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers.健康男性志愿者群体血浆和尿液药代动力学及磷霉素目标达成概率。
Eur J Clin Pharmacol. 2023 Jun;79(6):775-787. doi: 10.1007/s00228-023-03477-5. Epub 2023 Apr 15.
5
In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Clinical Isolates.磷霉素与美罗培南或多粘菌素B联合应用对产KPC-2临床分离株的体外和体内协同作用
Antibiotics (Basel). 2023 Jan 23;12(2):237. doi: 10.3390/antibiotics12020237.
6
Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.口服磷霉素对体外动态膀胱感染肺炎克雷伯菌的活性。
J Antimicrob Chemother. 2022 Apr 27;77(5):1324-1333. doi: 10.1093/jac/dkac045.
7
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).抗生素耐药性、药物靶点达成率、细菌致病性和毒力,以及抗生素的可及性和可负担性对新生儿败血症结局的影响:一项国际微生物学和药物评价前瞻性子研究(BARNARDS)。
Lancet Infect Dis. 2021 Dec;21(12):1677-1688. doi: 10.1016/S1473-3099(21)00050-5. Epub 2021 Aug 9.
8
Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species.通过抑制多种酵母物种中的多药外排和 Pma1 表达,将 FDA 批准的抗癌药物 ponatinib 重新用作氟康唑增效剂。
Microb Biotechnol. 2022 Feb;15(2):482-498. doi: 10.1111/1751-7915.13814. Epub 2021 May 6.
9
Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.用于全身性细菌感染的持续或延长输注的磷霉素:对其体外、体内及临床研究给药方案建议的系统评价
Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1117-1126. doi: 10.1007/s10096-021-04181-x. Epub 2021 Feb 18.
10
Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Infection.基于蒙特卡洛模拟的磷霉素给药方案用于治疗耐碳青霉烯类感染
Infect Chemother. 2020 Dec;52(4):516-529. doi: 10.3947/ic.2020.52.4.516. Epub 2020 Oct 26.